Two-day Discussion On ASEAN Youth Mental Health Draws 135 Participants
KOTA KINABALU, June 29 (Bernama) -- A total of 135 participants from ASEAN member states and Timor Leste attended the two-day Roundtable Discussion: ASEAN Youth Mental Health 2025 held here, which began yesterday.
Minister of Youth and Sports Hannah Yeoh said the forum brought together participants from various backgrounds, including mental health experts, religious figures, policymakers, government officials, civil society representatives and youth.
In the Malaysian context, she said the forum was crucial as findings from the Malaysian Youth Mental Health Index Study 2023 (MyMHI'23) indicated that the mental health of youths aged 15 to 30 remained at a moderate level.
"For a serious issue like this, the government needs the involvement of all parties to come together and discuss. In this case, we need the cooperation of medical experts, youth representatives and religious groups," she said after opening the programme here today.
Meanwhile, the Institute for Youth Research Malaysia (IYRES) Acting Chief Executive Officer Shahhanim Yahya said that today's youth appear to struggle with their self-identity, as they are increasingly open about expressing emotions and stress on social media.
"The scope of stress is broad, and this is why it's important for us to better understand the youth...to determine whether the cause of stress stems from within themselves or from their surrounding ecosystem," she said.
Themed "ASEAN Youth Voice: Empowering Minds, Ensuring Well-being", the programme aims to address the mental health challenges of ASEAN youth through regional cooperation, exchange of best practices and promoting inclusive advocacy to increase mental health literacy and improve access to mental health care.
-- BERNAMA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
3 hours ago
- New Straits Times
NST Leader: Tough battle as drug trends shift
The drug scourge has been with Malaysian society for as long as we can remember. "Traditional" drugs such as ganja and heroin had dominated the scene, topping the National Anti-Drugs Agency's (AADK) annual list of substances favoured by addicts. However, last year marked a sharp shift in the trend, with synthetic drugs such as ecstasy and methamphetamine overtaking traditional drugs as the narcotics of choice. Take the latest troubling statistics: Of the 193,000 addicts arrested or who voluntarily surrendered, 60 per cent were hooked on synthetics, outpacing heroin and ganja abuse. They were attracted to the drugs because of easy access, lower prices and more potent effects. AADK director-general Datuk Ruslin Jusoh, in an interview with the New Straits Times, said synthetic drugs have become the favoured narcotics of the younger generation, namely addicts aged between 19 and 39. They make up almost 70 per cent of those hooked on synthetic drugs. Why this shift to synthetics? It's a complex mix of social, psychological, economic and environmental factors. There's the party and clubbing culture: drug-using peers increase exposure and favourable attitudes, thrill-seeking and experimentation. There's also the misplaced perception that synthetics are "safe and legal" because peddlers' market them as "legal highs", labelling products as "incense" and "potpourri" to mislead users. The downside is severe and unpredictable side-effects: trauma, mental health problems, family conflict, stress and poor self-image. Another effect of the popularity of synthetic drugs, according to Roslin, is the perception among youths that ganja is a "safer" option. This has inadvertently fulfilled the age-old adage of ganja being a gateway drug, looping in fledgling users to experiment with stronger, more potent narcotics. Hindsight, they say, is 20-20. Given current developments, it would appear that Malaysia has dodged a bullet when a 2022 movement to legalise "medical" marjuana in the country failed to take off. Even Thailand, which had decriminalised marijuana in 2022 — a first for Southeast Asia — this week reimposed restrictions on the drug. All these only serve to underscore the harsh reality that despite decades of government and community approach involving education, early intervention, treatment and support, eradicating drugs is a monumental battle. While the temptation to capitalise on the potential economic benefits is there, it is undoubtedly too high a price to pay.
Barnama
8 hours ago
- Barnama
Pharma Industry Emerging As Driver Of Investments, Jobs, And Healthcare Resilience -- MPC
BUSINESS KUALA LUMPUR, June 30 (Bernama) -- Malaysia's pharmaceutical industry is emerging as a driver of high-value investment, skilled employment, and healthcare resilience, driven by regulatory and productivity reforms implemented in recent years, according to the Malaysia Productivity Corporation (MPC). MPC said these efforts have also supported Malaysia's climb to 23rd place in the 2025 International Institute for Management Development (IMD) World Competitiveness Ranking, the country's highest position in over a decade. 'Under the MPC, the Pharmaceutical Productivity Nexus (PPN) has driven structural changes that translate directly into economic value by streamlining product registration processes, aligning technical requirements across agencies, and reducing regulatory bottlenecks,' it said in a statement today. According to the MPC, two new pharmaceutical facilities have progressed to the development stage, unlocking investments and creating skilled employment opportunities, while two additional facilities are moving forward more rapidly under the streamlined processes. MPC director general Datuk Zahid Ismail said the sector's transformation provides a blueprint for national economic renewal. 'Every bottleneck removed is an opportunity unlocked, whether it's faster factory approvals, increased export readiness, or local production of critical medicines,' he added. The president of the Malaysian Organisation of Pharmaceutical Industries (MOPI) and PPN representative, Ch'ng Kien Peng, said the pharmaceutical sector's gains reflect what is possible when productivity reforms are targeted, data-driven, and collaborative. 'These wins go beyond industry metrics. They mean better access to affordable medicines, more quality jobs for Malaysians, and increased resilience in our healthcare supply chain,' he said. The MPC also stated that the sector's progress aligns with the objectives of the 12th Malaysia Plan, the New Industrial Master Plan 2030, and the National Energy Transition Roadmap by supporting economic growth and localised production of essential medicines while integrating environmental sustainability practices in facility operations. It added that continued investment in automation, digitalisation, and skills development by industry players will help sustain these gains, while support from the government in advancing mutual recognition agreements and inter-agency frameworks remains important to maintain momentum in the sector. --BERNAMA
New Straits Times
8 hours ago
- New Straits Times
Malaysia no longer just competing but leading: Industry chief
KUALA LUMPUR: Malaysia's rise in the IMD World Competitiveness Ranking 2025 reflects the tangible outcomes of strategic and productivity-driven reforms, with the pharmaceutical sector emerging as a standout contributor to the success. Pharmaceutical Productivity Nexus (PPN) champion and Malaysian Organisation of Pharmaceutical Industries president Ch'ng Kien Peng said Malaysia is no longer just competing but leading. Ch'ng said the pharmaceutical sector's gains reflect what is possible when productivity reforms are targeted, data-driven and collaborative. "These wins go beyond industry metrics; they mean better access to affordable medicines, more quality jobs for Malaysians, and increased resilience in our healthcare supply chain," he said in a statement. Under Malaysia Productivity Corporation (MPC), the PPN has driven structural changes that translate directly into economic value. These include streamlining product registration processes, aligning technical requirements across agencies and reducing regulatory bottlenecks. As a result, the corporation said two new pharmaceutical facilities have successfully moved to development, unlocking millions in investment and new job opportunities. "Two additional facilities are progressing more rapidly, thanks to reduced duplication and stronger agency coordination. "Approval timelines have been shortened, giving Malaysian firms a competitive edge in time-to-market," it said. MPC director general Datuk Zahid Ismail said the sector's transformation offers a blueprint for national economic renewal. "Every bottleneck removed is an opportunity unlocked whether it's faster factory approvals, increased export readiness, or local production of critical medicines. "This is productivity with purpose, and its effects are measurable," said Zahid. To sustain and scale these results, MPC urged the industry to continue investing in automation, digitalisation and skills development. In addition, the government should accelerate mutual recognition agreements, innovation incentives and seamless inter-agency frameworks, it said.
